Pfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the drugmaker dropped its other similar treatment for the disorder in December, Kaori Yoshida and Hinako Bannon report. A Pfizer representative confirmed the move, calling it a business decision, the authors add.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Eli Lilly (LLY) Stockpiles Weight Loss Pill Ahead of Regulatory Approval
- Starboard Value buys Pfizer, exits Humana in Q4
- Senate votes to confirm Robert Kennedy as head of HHS
- Pfizer says Talzenna, Xtandi combination improved OS in mCRPC
- Pfizer’s Adcetris combination regimen approved by FDA for r/r DLBCL